Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
abbvie
allergan aesthetics
alzheimer's disease
amgen
archive
astrazeneca
athira pharma
attralus
biontech
biotech
boehringer ingelheim
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
cancer
cancer drugs
chiesi farmaceutici
cholestatic liver diseases
click therapeutics
coronavirus
covid-19
cullinan oncology
cystic fibrosis
daniel o'day
deals
detroit blog main
detroit top stories
diabetic macular edema
diagnostics
dogma therapeutics
dyne therapeutics
eli lilly
escape bio
escient pharmaceuticals
europe blog main
europe top stories
finch therapeutics
gene editing
gilead sciences
What
ceo
2
×
drug
2
×
gilead
sciences
2
×
acquisitions
addressed
answers
big
biggest
bio
build
buy
company’s
cost
covid
daniel
debut
dyne’s
early
hasten
indicated
medicine
microbiome
moves
openly
o’day
pipeline
positive
question
recove
remdesivir
roundup
scores
seagen
spoken
surrounding
treatment
trials
way
week
Language
unset
Current search:
ceo
×
drug
×
sciences
×
@xconomy.com
3 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@slashgear.com
3 years ago
Gilead CEO answers big COVID-19 question: How much will remdesivir cost
